



Desoxyn® (methamphetamine)
Effective 04/17/19

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Desoxyn® (methamphetamine) is a member of the amphetamine group of sympathomimetic amines indicated for Attention Deficit Hyperactivity Disorder (ADHD) as an integral part of a total treatment program and Exogenous Obesity as a short term adjust in a regimen of weight reduction based on caloric restriction for patients in whom obesity is refractory to alternative therapy (e.g., repeated diets, group programs, other drugs).

Coverage Guidelines

Authorization may be granted when the following criteria are met:

1. Member has a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) **AND**
2. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to a trial (defined as ≥ 7 days of therapy) to ALL other stimulant and non-stimulant options

Note: Additional criteria may apply for members under the age of 18. Please refer to the MassHealth Pediatric Behavioral Health Medication Initiative guideline for criteria.

Continuation of Therapy

Reauthorization requires physician documentation indicating a positive response to therapy.

Limitations

1. Approvals will be granted for 12 months

Appendix



Adverse reactions/contraindications to stimulants include but are not limited to weight loss or failure to gain weight, insomnia, agitation, increased anger and aggression, tic disorder, seizures w/ ADHD, traumatic brain injury w/ ADHD (trial of **both** a methylphenidate product and amphetamine product is required for approval), symptomatic heart disease in children (tachycardia or hypertension), symptomatic heart disease in adults (there should be at least 1 failed trial of another non-stimulant medication that may be used for ADHD such as bupropion.)

References

1. Desoxyn (methamphetamine) [package insert]. Lebanon (NJ): Recordati Rare Diseases Inc; 2019 March

Review History

03/01/18 – Effective (adopted MH RS)

04/17/19 – Reviewed in P&T Meeting

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.